close
News Release

For Immediate Release

Second HCV CME/CE Activity in Johns Hopkins University School of Medicine/Med-IQ Educational Collaboration Now Available for Healthcare Providers

COMPLIMENTARY CME/CE

Exploring Emerging Treatment Options in the Context of Holistic HCV Treat-Or-Defer Decisions

Read today: www.Med-IQ.com/a726



Charting a Successful Treatment Course in HCV: A Comprehensive Approach to the Informed Treat-or-Defer Decision

Read today: www.Med-IQ.com/a705

Jointly presented by the
Johns Hopkins University
School of Medicine
and Med-IQ.




BECOME A MED-IQ MEMBER FOR FREE

Sign up today and access
award-winning medical education.
Learn more about your
member benefits.

Have questions?
Contact a Med-IQ Concierge Specialist. Call (toll-free)
866 858 7434 or e-mail
info@med-iq.com.

Med-IQ.
Inspiring Medical Education.

BALTIMORE, MD—October 9, 2013—Med-IQ, an award-winning, ACCME-accredited provider of continuing medical education (CME), is pleased to announce the availability of the second hepatitis C virus (HCV) CME/CE activity in its educational collaboration with Johns Hopkins University School of Medicine.

Exploring Emerging Treatment Options in the Context of Holistic HCV Treat-Or-Defer Decisions is an online publication designed for healthcare professionals who treat patients with HCV, including hepatologists, gastroenterologists, and infectious disease specialists.

The treatment landscape for chronic HCV is changing rapidly, however, current HCV guidelines do not provide concrete direction to guide clinicians as they determine which patients need prompt initiation of antiviral therapy and which patients may be eligible for informed deferral of treatment. This activity reviews emerging agents for the treatment of patients with chronic HCV and the impact of recent trial data on the treat-or-defer conversation.

“The decision of whether to initiate therapy for patients with HCV or defer until additional options are available is quite complex and requires a holistic thought process that considers a multitude of factors,” said William A. Mencia, MD, CCMEP, Vice President of Education and Medical Affairs at Med-IQ. “We are honored and pleased to partner with the Johns Hopkins University School of Medicine to offer this educational series exploring the evolving landscape of HCV management."

FACULTY

Mark Sulkowski, MD (Activity Director)
Professor of Medicine
Medical Director, Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology
Johns Hopkins University School of Medicine
Baltimore, MD

Wayne C. Campbell, MD
Associate Professor, Department of Medicine
University of Maryland School of Medicine
Chief, Division of Infectious Diseases
Union Memorial Hospital
Baltimore, MD

Judith Myers, CRNP
Baltimore VA Medical Center
Baltimore, MD

Clinicians are invited to visit www.Med-IQ.com/a726 for complimentary access to this educational opportunity. The first activity in this CME/CE series, Charting a Successful Treatment Course in HCV: A Comprehensive Approach to the Informed Treat-or-Defer Decision, can be accessed here.

For more information, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com.

Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Johns Hopkins University School of Medicine and Med-IQ. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Med-IQ is accredited by the California Board of Registered Nursing to provide continuing education to nurses. Provider approved by the California Board of Registered Nursing, provider number CEP 14745, for 1.0 contact hour.

This activity is supported by educational grants from AbbVie Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Therapeutics, and Merck & Co., Inc.


About Med-IQ

Med-IQ, one of America's most respected providers of continuing medical education (CME), inspires healthcare professionals through award-winning activities that deliver sophisticated outcomes-based educational designs with measurable results in professional competence and performance. Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the California Board of Registered Nursing (CBRN), and the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing medical education to physicians, nurses, and pharmacists, respectively.

Med-IQ, a leader in the development of performance improvement (PI) and quality improvement (QI) CME initiatives, has been recognized by the Alliance for Continuing Education in the Health Professions for our excellence in CE research (William Campbell Felch Award 2013, 2011), educational collaborations (2013), outstanding CME outcomes assessment (2012), and exceptional leadership (Leadership Award 2013, President’s Award 2012). To learn more about Med-IQ, visit www.Med-IQ.com, like us on Facebook, follow us on Twitter, and connect with us on LinkedIn.


For more information, contact:

Catherine B. Mullaney, MHA
Vice President, Educational Partnerships
Med-IQ
866 858 7434
info@med-iq.com